Genetic therapies in neurodegeneration: cohorts, targets and approaches

The symposium will feature a keynote lecture from Dr Frank Bennett, Ionis Pharmaceuticals, on his groundbreaking work on antisense research. It will be followed by a series of short presentations from UCL researchers on gene therapy research and trials currently taking place here as well as cohorts who could potentially benefit. 

Full programme and registration details

Dr. Bennett is Senior Vice President of Research at Ionis Pharmaceuticals. He is responsible for preclinical antisense drug discovery and antisense technology research. Dr. Bennett is also the franchise leader for the Neurological Programs at Ionis. He is one of the founding members of the Company. Dr. Bennett has been involved in the development of antisense oligonucleotides as therapeutic agents, including research on the application of oligonucleotides for inflammatory, neurodegenerative diseases and cancer, oligonucleotide delivery, pharmacokinetics and medicinal chemistry. Dr. Bennett has published more than 175 papers in the field of antisense research and development and has more than 150 issued U.S. patents. More info : http://www.ionispharma.com/c-frank-bennett-ph-d/

Streaming link:  https://www.youtube.com/watch?v=cfD5SU8Mrvc Available live and after the event. Join us in the debate: #UCLDementiaSeminars #QSCNMD

Further information: Elizabeth Halton; e.halton@ucl.ac.uk